The National Institutes of Health-sponsored, Johns Hopkins All Children’s Hospital-led Kids-DOTT clinical trial recently enrolled its 500th patient as the Kids-DOTT Investigator Group held its investigator meeting last month at the American Society of Hematology annual meeting in San Diego.
This multinational randomized trial studies the optimal length of treatment with anti-clotting medications in patients under 21 years of age with blood clots in the veins or lungs (venous thromboembolism, VTE).
With more than 50 centers participating from across the United States, Canada, Europe and Australia, and the recent milestone of 500-plus patients enrolled, Kids-DOTT is the largest trial undertaken in the field of pediatric VTE.
In addition, this Johns Hopkins All Children’s-led international collaboration has established the field’s most expansive multicenter trial-derived biobank of plasma, RNA and DNA in this disease that affects a growing number of children each year.
“I’m so thankful for the opportunity to lead such a passionate, devoted and expert group of global investigators, as well as research professionals at the Johns Hopkins All Children’s-based Kids-DOTT Trial Coordinating Center, in this critical effort,” remarks overall Kids-DOTT Principal Investigator Neil Goldenberg, M.D., Ph.D., professor of pediatrics and medicine at the Johns Hopkins University School of Medicine, chief research officer for the All Children’s Research Institute, and director of the thrombosis and stroke programs at Johns Hopkins All Children’s.
“More importantly,” adds Goldenberg, “my colleagues and I are so grateful to all the patients and their families who share and inspire our passion for research, and whose generous participation in the study is a tremendous gift for the benefit of future children with VTE.”